 |
 |
 |
 |
 |
 |
On June 5th, 2017, SGC Oxford's Kilian Huber was awarded a Bronze level Thermo Scientific Tandem Mass Tag (TMT) Research Award. The award recognizes scientists conducting innovative research with potential impact in proteomics. The award includes a $5,000 prize to be used towards ThermoFisher reagents.
Each semester, SGC-Toronto hosts a team of senior law students from the University of Toronto's Faculty of Law as part of an externship clinic to provide the students with experience in open science law while helping SGC draft new agreements that protect our open access ethos and promote our open science. One team of lawyers-to-be under the guidance of law faculty and practicing lawyers redefined 'trust' laws to ensure the usage of SGC's distributed chemical probes remains in the interest of the public. The team published a paper in the Journal Science Translational Medicine on this new mechanism to sharing open science resources.
In this piece posted on WIRED on July 17th 2017, Menaka Wilhelm describes the reasons why SGC has chosen to practice "extreme openness" in drug design by sharing data and research material with the world. This open approach is supported by SGC's pharma partners, the pharmaceutical companies that fund and collaborate with the SGC, and by SGC's public funders who collectively recognize the value of open-source science in speeding up drug discovery and ultimately developing new medicines to save patients' lives.
June 16th, 2017- SGC’s Target Enabling Package (TEP) Evaluation Group has approved five new TEPs for protein targets related to cancer, metabolic diseases and neuropsychiatric disorders.
TEPs enable scientists to research understudied proteins that have been genetically linked to human disease. The SGC generates and disseminates structural data, assays and other key research information and tools on these proteins to the scientific community.
The five TEPs recently released focus on the following genes:
Scientists have utilised Diamond Light Source to develop a new method to extract previously hidden information from the X-ray diffraction data that are measured when resolving the three-dimensional (3D) atomic structures of proteins and other biological molecules.
The international research consortium SGC and SciLifeLab aim to give researchers access to well-validated research tool antibodies.
[by Susanne Gräslund, SGC Karolinska, Helena Persson Lotsholm,DDDP SciLifeLab, Per I Arvidsson, Director DDDP SciLifeLab, Mikael Sundström, Director SGC European activities]
SGC and Abbvie scientists have published a research article in Nature Chemical Biology reporting a chemical probe for embryonic ectoderm development (EED) protein. The open-access probe, A-395, binds to EED inhibiting protein-protein interaction and inactivating the Polycomb repressive complex 2 (PRC2). PRC2 is dysregulated in many cancers and is a potential target for therapy.
Earlier this month, SGC and Abbvie reported on another collaboration resulting in A-196, a first-in-class open-access inhibitor against SUV4-20.
The IFOPA and FOP Friends® UK have joined together to co-fund a new study at the University of Oxford.
Alex Bullock, who established the University of Oxford FOP Research Team with Professor Jim Triffit, is optimistic that this new research technique “could lead to the development of a new class of inhibitor drug for FOP therapy.”
